Immunotherapy Failure in Glioblastoma: A Systematic Review and Meta-analysis of Randomized Controlled Trials - PubMed
4 hours ago
- #immunotherapy
- #glioblastoma
- #meta-analysis
- Immunotherapy has not demonstrated survival benefits in glioblastoma despite early-phase signals of activity.
- A systematic review and meta-analysis of 12 randomized controlled trials (RCTs) was conducted.
- Immunotherapy was associated with significantly worse overall survival (OS) compared to control (pooled HR = 1.16, 95% CI 1.06-1.28).
- No improvement in progression-free survival (PFS) was observed (pooled HR = 0.93, 95% CI 0.70-1.24).
- Objective response rate (ORR) showed heterogeneous, non-survival-concordant signals (OR = 1.17, 95% CI 0.91-1.51).
- Phase III trial status was identified as the dominant predictor of unfavorable OS effects.
- The study concludes that immunotherapy does not improve survival in glioblastoma, with inconsistent signals in PFS and ORR.